Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 874 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Carcinoma Clear all
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

NCT06607874
View directory record Official record
Conditions
Human Papillomavirus-Related Cervical Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

NCT02868892
View directory record Official record
Conditions
Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix
Interventions
Pemetrexed
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06904365
View directory record Official record
Conditions
Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer

NCT01287871
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
supportive care
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Withdrawn Phase 1 Interventional

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

NCT04411134
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 20, 2026, 5:28 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934
View directory record Official record
Conditions
Cancer of the Uterine Cervix
Interventions
Not listed
Lead sponsor
Trans Tasman Radiation Oncology Group
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

NCT00003384
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Cervical Cancer
Interventions
Cervical Papanicolaou Test, Conization, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 20, 2026, 5:28 AM EDT
Withdrawn No phase listed Observational

Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

NCT00736216
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
survey administration
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

NCT00006083
View directory record Official record
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

NCT00790569
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine, varenicline, placebo
Drug · Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake

NCT03337269
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma
Interventions
Educational video, Educational handout, Control
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years to 26 Years · Female only
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors

NCT02046265
View directory record Official record
Conditions
Cervical Cancer
Interventions
Step Up to Prevention, Step Up to Prevention: knowledge, Step Up to Prevention:belief, Offered HPV vaccine only
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 20, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients

NCT02401867
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Sexually Transmitted Diseases
Interventions
Not listed
Lead sponsor
Fenway Community Health
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

NCT00005941
View directory record Official record
Conditions
Cervical Cancer, Vaginal Cancer
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 20, 2026, 5:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT03260023
View directory record Official record
Conditions
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Interventions
TG4001, Avelumab
Biological · Drug
Lead sponsor
Transgene
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

NCT00799825
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
39
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 20, 2026, 5:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Breast Cancer
Interventions
ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
Drug
Lead sponsor
Ensem Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Research in Ethno-Medicine and Education (REMED)

NCT05907187
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus, HPV, Human Papillomavirus Infection
Interventions
Cervical Cancer Prevention Education
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

NCT02558348
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer, Cervical Cancer
Interventions
AL3818
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 20, 2026, 5:28 AM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 20, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial

NCT00509444
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer, Lung Cancer
Interventions
Educational materials, educational materials, plus patient navigation
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 20, 2026, 5:28 AM EDT